Zacks Investment Research upgraded shares of ENANTA PHARMA (ENTA) from NEUTRAL to OUTPERFORM on October 02, 2013, with a target price of $25.40.
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ENANTA PHARMA (ENTA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment